Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada | Zendy

Maile Karris | Zendy; Susan E. Beekmann | Zendy; Sagar Mehta | Zendy; Christopher M. Anderson | Zendy; Philip M. Polgreen | Zendy

Open Access

Are We Prepped for Preexposure Prophylaxis (PrEP)? Provider Opinions on the Real-World Use of PrEP in the United States and Canada

Author(s) -

Maile Karris,

Susan E. Beekmann,

Sagar Mehta,

Christopher M. Anderson,

Philip M. Polgreen

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit796

Subject(s) - pre exposure prophylaxis , emtricitabine , medicine , serodiscordant , tenofovir , disease control , placebo , family medicine , drug approval , men who have sex with men , alternative medicine , drug , human immunodeficiency virus (hiv) , pharmacology , virology , antiretroviral therapy , syphilis , viral load , pathology

Preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine (Truvada) has demonstrated efficacy in placebo-controlled clinical trials involving men who have sex with men, high-risk heterosexuals, serodiscordant couples, and intravenous drug users. To assist in the real-world provision of PrEP, the Centers for Disease Control and Prevention (CDC) has released guidance documents for PrEP use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research